Braun Stacey Associates Inc. Increases Stake in Johnson & Johnson

The institutional investor now owns nearly 150,000 shares of the healthcare giant.

Apr. 8, 2026 at 7:50am

Got story updates? Submit your updates here. ›

A high-contrast black and white image depicting the intricate gears and mechanisms of a large, industrial banking vault, representing the financial security and institutional power of the healthcare company Johnson & Johnson.The robust financial infrastructure and institutional strength of Johnson & Johnson, a healthcare industry titan, are visually represented through an extreme close-up of the company's complex banking operations.New Brunswick Today

Braun Stacey Associates Inc., an institutional investor, has increased its stake in Johnson & Johnson (NYSE: JNJ) by 9.9% in the fourth quarter, according to a recent 13F filing with the Securities and Exchange Commission. The firm now owns 148,856 shares of the company's stock, valued at $30.8 million.

Why it matters

Johnson & Johnson is a bellwether healthcare stock, and institutional investor activity in the company's shares can signal broader market trends and investor sentiment around the stock. Braun Stacey's increased position suggests confidence in JNJ's outlook.

The details

According to the 13F filing, Braun Stacey Associates Inc. acquired an additional 13,411 shares of Johnson & Johnson during the fourth quarter. The firm's total position in JNJ now accounts for 1.0% of its overall portfolio, making it the 29th largest holding.

  • The 13F filing covers the fourth quarter of 2025.
  • Braun Stacey increased its JNJ stake by 9.9% during that period.

The players

Braun Stacey Associates Inc.

An institutional investment firm that has increased its stake in Johnson & Johnson.

Johnson & Johnson

A multinational healthcare company that develops, manufactures, and markets pharmaceutical, medical device, and consumer health products.

Got photos? Submit your photos here. ›

The takeaway

Braun Stacey's increased position in Johnson & Johnson suggests continued institutional confidence in the healthcare giant's outlook, even as the stock trades near all-time highs. Investors will likely watch for further updates on JNJ's performance and any additional changes to major shareholders' positions.